First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Upcoming events – Biomarin’s achondroplasia hope and Apellis’s clash with Alexion
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
Uncovering biopharma’s hidden treasures
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Novo goes early to leapfrog haemophilia gene therapies
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Two more patients bolster Sangamo’s haemophilia A gene therapy
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.